Experienced in Thrush

Cecile Borel

Toulouse, FR 
Experienced in Thrush
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Cecile Borel practices in Toulouse, France. Ms. Borel is rated as an Experienced expert by MediFind in the treatment of Thrush. Her top areas of expertise are Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Adult Immune Thrombocytopenia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 50 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Thrush.

Gender
Female

Locations

Toulouse, France
Other Locations
Strasbourg, France
Nancy, France
Angers, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Brentuximab
Study Phase: Phase 2
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Enrollment Status: Completed
Publish Date: July 26, 2021
Intervention Type: Drug, Radiation
Study Drugs: Brentuximab, Cyclophosphamide, Adriamycin, Oncovin, Bleomycin, Etoposide, Procarbazine, Prednisone, Filgrastim
Study Phase: Phase 2
View 1 Less Clinical Trial

50 Total Publications

Myeloid/lymphoid neoplasm with PCM1::JAK2 rearrangement presenting as secondary Burkitt lymphoma.
Myeloid/lymphoid neoplasm with PCM1::JAK2 rearrangement presenting as secondary Burkitt lymphoma.
Journal: Annales de biologie clinique
Published: October 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Borel's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile